Practical considerations for active machine learning in drug discovery.

Drug Discov Today Technol

Koch Institute for Integrative Cancer Research and MIT-IBM Watson AI Lab, Massachusetts Institute of Technology, Cambridge, MA, USA; Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

Published: December 2019

Active machine learning enables the automated selection of the most valuable next experiments to improve predictive modelling and hasten active retrieval in drug discovery. Although a long established theoretical concept and introduced to drug discovery approximately 15 years ago, the deployment of active learning technology in the discovery pipelines across academia and industry remains slow. With the recent re-discovered enthusiasm for artificial intelligence as well as improved flexibility of laboratory automation, active learning is expected to surge and become a key technology for molecular optimizations. This review recapitulates key findings from previous active learning studies to highlight the challenges and opportunities of applying adaptive machine learning to drug discovery. Specifically, considerations regarding implementation, infrastructural integration, and expected benefits are discussed. By focusing on these practical aspects of active learning, this review aims at providing insights for scientists planning to implement active learning workflows in their discovery pipelines.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ddtec.2020.06.001DOI Listing

Publication Analysis

Top Keywords

active learning
20
drug discovery
16
machine learning
12
active
8
active machine
8
learning
8
learning drug
8
discovery pipelines
8
discovery
6
practical considerations
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!